Literature DB >> 22342937

Adequate control of primary EBV infection and subsequent reactivations after cardiac transplantation in an EBV seronegative patient.

F L Pietersma1, A van Oosterom, L Ran, R Schuurman, E Meijer, N de Jonge, D van Baarle.   

Abstract

EBV seronegative recipients of cardiac transplantation are at risk for development of post transplant lymphoproliferative disease following primary EBV infection due to the ongoing treatment with immunosuppressive drugs. Here we present detailed kinetics of the EBV-specific T-cell response following cardiac transplantation in an EBV seronegative recipient who developed a primary EBV infection 15weeks post transplantation and subsequent viral reactivations throughout follow up. The patient developed an EBV-specific CD8(+) T-cell response within 24days after first detection of the primary infection. Subsequently, an increased EBV-specific CD8(+) T-cell response developed upon viral reactivation, indicated by a threefold increase of EBV-specific CD8(+) T cells and increased IFNy production after stimulation with EBV-specific peptide pools. These data indicate that an EBV-specific T-cell response capable of adequate control of a primary EBV-infection and subsequent viral reactivations can develop in an EBV seronegative cardiac transplant recipient in the presence of severe immunosuppression.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22342937     DOI: 10.1016/j.trim.2012.02.001

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  3 in total

Review 1.  The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.

Authors:  Olivia M Martinez; Sheri M Krams
Journal:  Transplantation       Date:  2017-09       Impact factor: 4.939

2.  Personalized adoptive immunotherapy for patients with EBV-associated tumors and complications: Evaluation of novel naturally processed and presented EBV-derived T-cell epitopes.

Authors:  Maren Bieling; Sabine Tischer; Ulrich Kalinke; Rainer Blasczyk; Søren Buus; Britta Maecker-Kolhoff; Britta Eiz-Vesper
Journal:  Oncotarget       Date:  2017-12-21

3.  Skewed T cell responses to Epstein-Barr virus in long-term asymptomatic kidney transplant recipients.

Authors:  Cecilia Nakid-Cordero; Nadia Arzouk; Nicolas Gauthier; Nadine Tarantino; Martin Larsen; Sylvain Choquet; Sonia Burrel; Brigitte Autran; Vincent Vieillard; Amélie Guihot
Journal:  PLoS One       Date:  2019-10-22       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.